Overexpression of CDKN2B is involved in poor gastric cancer prognosis

The objective of this investigation is to elucidate the clinical significance of cyclin‐dependent kinase inhibitor 2B (CDKN2B) expression regarding gastric cancer (GC), as well as to detect the involvement of CDKN2B expression in the clinicopathological indexes and prognosis of GC. Immunohistochemical analysis was used for identification of CDKN2B expression in GC specimens. Chi‐square (χ2) test was applied to detect the association of CDKN2B expression and clinicopathological parameters of GC. The involvement of CDKN2B expression in the prognosis was analyzed via univariate and multivariate analysis. It was indicated that relative to the corresponding para‐carcinoma tissues, CDKN2B expression was notably upregulated in GC specimens. Moreover, the expression of CDKN2B was strongly correlated with the differentiation (r = −0.182; P = .015), invasion (r = −0.157; P = .038), distant metastases (r = −0.196; P = .004), and TNM stage (r = −0.204; P = .005). Nevertheless, no remarkable variance was related to age, tumor loci, or sex. Kaplan‐Meier survival curve and univariate analysis showed that CDKN2B overexpression predicted poorer disease‐free survival (P = .007) and overall survival (P = .005) in those with GC. In addition, Cox proportional hazards regression model revealed that CDKN2B was an isolated biomarker of disease‐free survival and overall survival in patients with GC. Taken together, our data demonstrated that the overexpression of CDKN2B could be an isolated factor for GC prognostic in patients. CDKN2B gene may be a useful target and new treatment for improving the prognosis of GC. Overexpression of cyclin‐dependent kinase inhibitor 2B (CDKN2B)‐AS1 is an independent prognostic factor for patients with gastric cancer (GC). CDKN2B‐AS1 gene may be a useful target and new treatment for improving the prognosis of GC.